Lion (Stavudine) plays a role in the management of Human Immunodeficiency Virus (HIV) infection, including contexts involving advanced Acquired Immunodeficiency Syndrome (AIDS). Its core use is used to manage the effects of the underlying persistent viral condition. It is applied in addressing the underlying viral condition, which may assist with maintaining functional stability. This action may decrease the chance of developing AIDS and HIV-related illnesses such as serious infections or cancer.

The medication's primary benefit is considered relevant for supporting the maintenance of immune function. Its use is focused on achieving better long-term health outcomes. It helps alleviate symptoms related to systemic imbalance associated with HIV and contributes to easing the overall symptom load caused by severe opportunistic infections and related illness. This supports the patient during difficult episodes by easing distress. This supportive relief is relevant for: treating HIV-1 infection, preventing Mother-to-Child Transmission (PMTCT), and use as a component of Combination Antiretroviral Therapy (ART).

Lion is commonly used as a component of ART in adults and children with HIV-1 infection. For pregnant patients, it is applied in the critical context of PMTCT, and is considered relevant in reducing the risk of viral transmission to the infant, which assists with maintaining functional stability for the patient.

Quick Fact: Relief for Systemic Imbalance

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Lion (Stavudine) — Official Regulatory Information

Eligibility Classifications (High-Level)

Resulting Eligibility Structure

Official eligibility statements:

• Stavudine is contraindicated in patients with a clinically significant hypersensitivity to the drug or its components.
• Co-administration with didanosine is an official contraindication due to the high risk of serious toxicity.
• Patients with impaired renal function are subject to an official dose adjustment requirement to maintain eligibility.

Connection to the overall eligibility profile: Governmental regulatory documents define who can and cannot use Stavudine by establishing absolute contraindications and specifying conditions for conditional eligibility. Use is broadly eligible for adult and pediatric populations but requires special caution in the presence of organ impairment or risk factors for lactic acidosis, defining who may use the medicine and under what officially restricted circumstances.

Interactions with other medicines and products

Lion (Stavudine) interactions are primarily governed by the risk of additive toxicity and intracellular antagonism, as documented in regulatory prescribing information. The official profile establishes specific constraints on co-administration with other medicinal products.

Interaction Restrictions

Pharmacokinetic and Timing Notes

Certain agents, including Ribavirin and Doxorubicin, require caution as in vitro data indicate they inhibit Stavudine's phosphorylation. Regarding administration, Stavudine may be taken with or without food. For populations with renal impairment, official documentation confirms that decreased creatinine clearance reduces Stavudine clearance, resulting in increased systemic exposure. This physiological change necessitates an acknowledgment of potential exposure modification in this population.

Lion, known chemically as Stavudine, acts by directly interfering with the genetic replication of the virus inside host cells. It requires intracellular phosphorylation by host cell enzymes into its active form, d4T-TP, which then targets the essential viral enzyme HIV Reverse Transcriptase. By acting as a competitive inhibitor, d4T-TP is incorporated into the growing viral DNA strand, physically blocking the addition of subsequent genetic material and causing DNA chain termination. This molecular blockade slows the systemic rate of viral replication and reduces the rate of viral destruction of CD4^+ T-lymphocytes. While primarily designed for the viral enzyme, the active form of Stavudine also interacts with the host cell enzyme mitochondrial DNA polymerase gamma (gamma). This off-target inhibition impairs mitochondrial DNA synthesis, creating a physiological constraint where highly metabolic tissues, such as those in the peripheral nervous system, may experience altered function due to impaired energy production. The mechanism's effectiveness is further constrained by the virus's ability to mutate its Reverse Transcriptase enzyme, leading to a biological scenario where the intended inhibitory mechanism is overcome.

How to Use Lion: Official Administration Guidelines

Lion (Stavudine) is administered exclusively by the oral route as a required part of a combination antiretroviral therapy (ART) regimen. The medication is available as both capsules (typically 30 mg and 40 mg strengths) and a powder for oral solution (1 mg/mL concentration), providing flexibility for different patient needs.

Standard Dosing and Frequency

The standard adult dose is based on the patient's body weight, and the drug is taken twice daily (every 12 hours) to maintain consistent blood levels. For adults weighing 60 kg or more, the dose is 40 mg per administration. For adults weighing less than 60 kg, the dose is 30 mg.

Administration Context and Adjustments

Dosage may be taken with or without food. However, administration on an empty stomach is advised for optimal absorption, permitting a light meal only if necessary. The capsules can be carefully opened and the contents mixed with food for individuals unable to swallow them.

Specific adjustments are mandated for patients with reduced kidney function. Dose reduction is required for adult patients with a Creatinine Clearance (CrCl) of le 50 mL/min. For patients undergoing hemodialysis, the dose must be administered after the completion of the dialysis session to account for drug removal. Pediatric dosing is determined by weight, using a mg/kg calculation for infants and younger children.

Handling Missed Doses

If a dose is missed, it should be taken as soon as possible, and the patient should then resume the regular schedule. If the time for the next scheduled dose is very close, the missed dose should be skipped entirely to avoid double dosing.

Research evidence / Overview of Studies for Lion (Stavudine)

Evidence for Use in Managing HIV-1 Infection

Research examining Lion (Stavudine) has been studied for its use as part of a combination regimen with other antiretroviral medications, which is the established approach for managing Human Immunodeficiency Virus (HIV) infection. The available evidence includes both randomized controlled trials (RCTs) and observational cohort studies, which sometimes involved long follow-up periods. Researchers examined key outcomes related to the virus and the body's immune system, specifically monitoring viral load and CD4+ T-lymphocyte cell counts, which are parameters tracked in HIV research.

Studies report patterns observed where combination regimens that included Stavudine was studied for managing HIV infection in both adults and children. Much of the primary evidence for Stavudine is historical, meaning the research often reflects comparisons with older drugs or focuses on specific dose-sparing strategies, rather than contemporary first-line agents. Therefore, comparative evidence is lacking against all currently recommended newer NRTIs, and long-term effects are not fully established.

Evidence in the Prevention of Mother-to-Child Transmission (PMTCT)

Lion (Stavudine) was evaluated in clinical trials and observational public health studies focused on addressing the risk of HIV transmission from a pregnant individual to their infant. These studies examined multi-drug regimens where Stavudine was a component, and the primary outcome was monitored as the rate of HIV infection in the exposed infants. Findings indicate that regimens including Stavudine contributed to the broader evidence landscape for perinatal HIV infection. However, this evidence is predominantly historical, as the data available for Stavudine in this context were often gathered during a period when its use was common.

Long-Term Evidence and Durability of Response

Studies have explored the durability of the treatment effects associated with regimens containing Lion (Stavudine) over defined time intervals. While initial randomized controlled trials typically monitored patients for short-to-intermediate periods (often around 96 weeks), data show patterns related to outcomes that were tracked beyond this period through observational cohort studies. There is limited information for long-term outcomes specifically from contemporary, large-scale RCTs that directly compare Stavudine-containing regimens with all modern-day preferred regimens.

Common questions about Lion (FAQ)

Q: Is Lion considered a common or specialized type of medication?

According to official guidance, the use of Lion is generally restricted to patients who have no suitable alternative treatment options available. These regulatory recommendations stem from safety concerns and indicate that treatment should be limited to the shortest period necessary.

Q: Is Lion used for long-term or short-term treatment?

Official regulatory guidance states that treatment duration should be limited to the shortest period possible. This is because the risk of certain serious side effects, such as lipoatrophy (loss of body fat), can accumulate over time with long-term exposure.

Q: Is it possible to experience rare side effects with Lion?

Yes, official documents for Lion categorize potential side effects by frequency, including those that are Very Common, Common, and Infrequent. These documents also track adverse reactions where the precise incidence, or how often they occur, is not precisely known, which may include rare events.

Q: How are the potential side effects of Lion typically managed?

The management of potential side effects, as described in official documents, often involves monitoring and possibly adjusting the dose of the medicine. For serious adverse reactions, such as Peripheral Neuropathy (nerve damage) or severe Hepatic Toxicity (liver damage), temporary suspension or permanent discontinuation of treatment may be necessary.

Q: Does Lion commonly cause weight gain or weight loss?

Official regulatory information includes warnings about the risk of lipoatrophy, which is the localized loss of body fat, particularly in the face, limbs, and buttocks. This change in body composition is a documented safety pattern associated with long-term exposure to this medicine.

Q: Is Lion present in breast milk?

Official product information states that breastfeeding is not recommended while using this medicine. This restriction is in place because of the potential risk of passing the virus to the infant.

Q: What is the difference between Lion and other medications in the same drug class?

Official safety profiles highlight that this medicine is associated with a higher risk of certain severe side effects, such as lactic acidosis and lipoatrophy (loss of body fat). Due to these documented risks, its use is generally restricted in clinical practice compared to newer medicines in the same category.

Q: Is Lion a generic or a brand-name medication?

The active ingredient in this medicine is Stavudine, which is the generic, non-proprietary name. While it was previously marketed under the brand name Zerit, the medicine is now also widely available as generic Stavudine.

Q: What does the term 'contraindication' mean in relation to Lion?

In the context of the official product information for Lion, a contraindication represents a condition or factor that absolutely prohibits the use of the medicine. This includes known hypersensitivity to the drug or, specifically, co-administration with other medicines like Didanosine.

Q: Does Lion require any special monitoring or blood tests?

Yes, official documents emphasize the need for regular monitoring for signs of serious adverse reactions, including lactic acidosis and hepatic toxicity (liver damage). This monitoring typically involves physical exams and regular blood tests to check liver and kidney function and watch for changes related to these risks.

Q: What steps are usually taken if a patient experiences a serious adverse event with Lion?

Official regulatory guidance is specific about actions taken for serious events. If laboratory findings or clinical symptoms suggest a serious reaction, such as symptomatic hyperlactatemia or severe hepatic toxicity, the medicine is typically suspended or permanently discontinued immediately.

Q: How is Lion different from an over-the-counter medicine?

The key difference is the dispensing status: Lion is categorized as a prescription-only medication. Official documents confirm that Stavudine is available only with a doctor’s prescription and cannot be obtained as an over-the-counter medicine.

Q: Is there a maximum length of time Lion is typically prescribed?

Official guidance states that treatment duration should be limited to the shortest possible time necessary. This is because the incidence and severity of some serious side effects, such as lipoatrophy (loss of body fat), are cumulative and are associated with a patient’s overall duration of exposure to the medicine.

Q: Can Lion affect mood or mental state, according to regulatory data?

Yes, the regulatory safety profile lists several psychiatric adverse reactions. These commonly reported effects include conditions such as insomnia (difficulty sleeping), depression, anxiety, and abnormal dreams.

Q: Does Lion interact with alcohol?

While alcohol is not listed as a formal contraindication, patient information documents note that alcohol abuse is listed as a potential risk factor that can increase the severity of side effects, specifically peripheral neuropathy (nerve damage) and liver disease.

Q: Can Lion cause sleepiness or difficulty sleeping?

Yes, the official documentation lists insomnia, or difficulty sleeping, as a very common side effect. Sleepiness is also one of the reported adverse reactions that may occur while taking this medicine.

Q: Is it safe to drive or operate machinery while taking Lion?

Official regulatory guidance states that caution is necessary when driving or operating machinery. This is a common precaution until an individual knows how the medicine affects them, particularly because nervous system issues and headaches are among the reported side effects.

Q: What is the risk of overdose described in the official documents for Lion?

The regulatory information describing overdose indicates that symptoms may include an exaggeration of documented nervous system issues. These can present as worsening numbness, tingling, weakness, or pain in the hands or feet (peripheral neuropathy).

Q: What type of specialist typically prescribes Lion?

This medicine is typically prescribed by healthcare professionals, such as specialized doctors or clinicians, who have experience in the treatment of HIV infection. This is because of the medicine's specific use as part of a combination antiretroviral regimen.

Q: What does the official patient information leaflet say about stopping Lion?

Official patient information states that the medicine should not be stopped without the direction of a healthcare professional. Discontinuation can lead to severe outcomes, including a viral rebound (an increase in the virus) and the development of drug resistance to the medicine.

Q: Is there a risk of interaction if Lion is taken with herbal supplements?

Regulatory patient information notes the importance of informing a doctor about all herbal products and nutritional supplements being taken. This is so the doctor can monitor for potential side effects or unexpected interactions that may occur.

Q: How long did it take for Lion to receive official regulatory approval?

The active ingredient, Stavudine, received its initial US Food and Drug Administration (FDA) approval on June 27, 1994. This approval was obtained through an accelerated process to address the urgent medical need at the time.

How to Store and Dispose of Stavudine (Lion)

Official regulatory guidelines prescribe specific storage and handling requirements for Stavudine capsules and the oral solution.

Storage Requirements

Disposal Instructions

Unused or expired Stavudine should be disposed of in a manner that prevents consumption by people or pets. Do not flush the product down a toilet or pour it down a drain unless specifically instructed by a governmental drug Take-Back Program.